ZAI LAB (09688) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

HK Stock MarketDetailed Quotes

09688 ZAI LAB

Watchlist

25.750
-1.150-4.28%

Trading Mar 4 10:45 CST

28.23BMarket Cap-14.15P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Asian Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT NewswiresMar 3 10:45 ET
B of A Securities Downgrades Zai Lab to Neutral, Raises Price Target to $36.1
BenzingaMar 3 08:07 ET · Ratings
Zai Lab Analyst Ratings
BenzingaMar 3 08:05 ET · Ratings
Zai Lab Announces Participation in Investor Conferences in March 2025
BusinesswireMar 3 07:30 ET
BofA Securities Downgrades Zai Lab(ZLAB.US) to Hold Rating, Raises Target Price to $36.1
Moomoo NewsMar 3 05:31 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB) and Repligen (RGEN)
TipRanksMar 3 05:20 ET · Ratings

Comments

Sean Parker

Jan 23 02:01

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

$Zai Lab (ZLAB.US)$
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has received Orphan Drug Designation (ODD) from the U.S. FDA for ZL-1310, their first-in-class DLL3 antibody-drug conjugate (ADC) designed to treat small cell lung cancer (SCLC). The designation comes after promising results from an ongoing Phase 1a/1b study in patients with previously treated extensive-stage SCL...